🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Wegovy reaches Britain as NHS, private outlets receive weight loss drug

Published 05/09/2023, 09:57
Updated 05/09/2023, 18:36
© Reuters. FILE PHOTO: A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo
NOVOb
-

By Maggie Fick

LONDON (Reuters) -Britain's National Health Service and two online sellers told Reuters they had received their first supplies of keenly anticipated Wegovy in Britain on Tuesday, a day after Novo Nordisk (CSE:NOVOb) launched the weight-loss drug in its fifth market.

High market expectations and booming demand for Wegovy, shown to help patients reduce weight by around 15% when used alongside exercise and lifestyle changes, have boosted Novo's share price and helped make the Danish drugmaker Europe's most valuable listed company.

A NHS spokesperson confirmed to Reuters that the self-injection drug is now available through the NHS weight management scheme, where it will be prescribed for free.

Spokespeople for Simple Online Pharmacy and Juniper, a venture capital-backed online clinic focused on weight management, both told Reuters that they had received Wegovy stock from a wholesaler, but declined to say much they had.

With many countries facing mounting healthcare problems due to rising obesity levels, Novo has been unable to produce enough to meet demand for Wegovy, which is now available in the United States, Norway, Denmark, Germany and Britain.

A spokesperson declined to comment on the volume of Wegovy that Novo would deliver to Britain, but reiterated the Danish company's statement on Monday that its launch would be "limited and controlled" due to supply constraints.

Novo said when announcing the launch in Britain that Wegovy will be available on the National Health Service's (NHS) weight management scheme and on the private market.

The Novo spokesperson said deliveries of Wegovy to a UK wholesaler had begun, but declined to comment on Simple Online Pharmacy's statement that it had already received the drug.

Novo delivers its medicines to the wholesaler, which is then in control of onward distribution, the spokesperson said, declining to name the wholesaler involved.

The sole UK wholesaler for Wegovy is Alliance Healthcare UK, a spokesperson for Juniper told Reuters on Monday.

© Reuters. A Simple Online Pharmacy weight care provider unpacks Wegovy stock, at the Simple Online Pharmacy Headquarters, in Glasgow, Britain, September 5, 2023. Simple Online Pharmacy/Handout via REUTERS

Alliance Healthcare UK on Tuesday afternoon confirmed to Reuters that it is a wholesaler distributor of Wegovy in the country. "Alliance Healthcare strives to distribute available stock to allow all customers to access Wegovy," the company said in an e-mailed statement in response to questions.

Some doctors and medical experts warned on Monday that people in Britain who can afford to pay out of their own pocket may get easier access to Wegovy than those seeking treatment in the country's state-run health service.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.